Home / Partner Index / Networks With Weight Loss and Diet Offers
8 networks active in this category · Updated September 2026 · A Blue Book PartnerIndex directory
Weight loss affiliate networks carry offers for diet supplements, weight management programs, meal delivery, fitness apps, and the fast-growing category of prescription weight loss. Demand is high year-round, and compliance scrutiny on claims and billing is just as high. Read our full guide to Weight Loss / Diet ›
This is a PartnerIndex directory: it lists the networks active in Weight Loss / Diet, with featured partners shown first and the rest in rotating order. It is not a ranking.
Maintained by the Blue Book editorial team.
Join the Network Partner Program to appear in this directory and the featured rotation.
Weight loss affiliate networks carry offers for diet supplements, weight management programs, meal delivery services, fitness apps, weight loss subscription services, and the rapidly growing category of GLP-1 telehealth programs. Weight loss is one of the FTC’s explicit priority enforcement areas for advertising claims, and that enforcement has intensified significantly with the surge of consumer interest in GLP-1 weight loss drugs like Ozempic and Wegovy. In December 2025, the FTC finalized an order against telehealth provider NextMed for using deceptive advertising claims, fake reviews, and misleading pricing to sell GLP-1 weight loss memberships. That case signals the agency’s attention to the intersection of weight loss marketing and the GLP-1 phenomenon.
Weight loss overlaps with the broader nutra vertical on supplement offers but extends well beyond supplements into diet programs, fitness subscriptions, meal plans, and now telemedicine services. The FTC’s enforcement on weight loss claims is more specific and more aggressive than general supplement enforcement, targeting the exaggerated results claims (“lose 30 pounds in 30 days”), deceptive before/after imagery, and unsubstantiated “clinically proven” assertions that have defined weight loss advertising for decades.
FTC claim scrutiny on weight loss advertising is the strictest in any consumer vertical. The FTC maintains dedicated weight loss advertising guidance, and its enforcement record demonstrates willingness to pursue cases aggressively. Specific claims that trigger enforcement include: guaranteed weight loss results without diet or exercise, specific pounds-lost claims without substantiation (“lose 30 pounds”), before/after imagery that does not represent typical results, “clinically proven” efficacy claims for supplements without adequate clinical evidence, and fake testimonials or fabricated reviews. The NextMed enforcement (2025) added GLP-1-related deceptive claims to the agency’s active enforcement priorities. Before promoting any weight loss offer, evaluate the landing page and promotional materials against FTC guidance. If the claims would not survive an FTC review, the offer is a compliance risk regardless of payout.
GLP-1 telehealth offers are the newest and fastest-growing segment, and they carry specific regulatory risks. The explosion of consumer interest in prescription weight loss medications has created a wave of telehealth programs marketing GLP-1 access through affiliate channels. The FTC’s NextMed case targeted deceptive pricing (hidden membership costs), unsubstantiated weight loss claims, and fake reviews in this exact category. The compounded side of this vertical has effectively closed, and any offer still built on it should be treated as a liability rather than an opportunity. The FDA resolved the semaglutide shortage in February 2025, which ended the basis for shortage-driven compounding, and enforcement discretion for outsourcing facilities ran out that May. In March 2026 the agency issued more than fifty warning letters to telehealth firms and compounding pharmacies in a single coordinated action, and in April 2026 it proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list altogether. Hims, Ro and the other large platforms have exited compounded semaglutide. If a network is still offering compounded GLP-1 campaigns, ask what the prescribing pathway is before you send a click, because the honest answers have narrowed to patient-specific 503A compounding in limited circumstances. Evaluate GLP-1 offers with extra scrutiny: are the pricing and membership terms clearly disclosed? Are the weight loss claims substantiated? Does the telehealth provider actually prescribe the medications advertised, or does the program bait with GLP-1 promises and switch to supplement alternatives? Is the provider relying on compounding exemptions that may no longer apply?
Offer structure in weight loss spans multiple models. Supplement offers typically run on the trial-to-subscription CPA model described on the nutra page, with the same chargeback and billing concerns. Meal delivery and prepared food programs run on CPA or CPS with subscription economics. Fitness apps and weight management programs run on CPA for trial signups or subscription activations. Telehealth programs typically run on CPL or CPA. Each model has different compliance requirements and different risk profiles. A weight loss supplement trial is a fundamentally different offer from a GLP-1 telehealth lead, and your evaluation criteria should reflect that.
Traffic source restrictions follow the pattern for health supplements. Google and Meta restrict weight loss advertising, particularly claims about specific results, supplement efficacy, and before/after imagery. Native advertising networks accept weight loss but may require compliance review. SEO content targeting weight loss search intent converts well for programs and products that genuinely deliver value. Evaluate the network’s traffic source guidance specifically for weight loss, not generic health supplement guidance.
Before/after content is the most regulated creative format in weight loss advertising. The FTC requires that before/after images reflect typical results, not exceptional outcomes. If the promotional materials show a 50-pound transformation but the typical user loses 5 pounds, those images are deceptive. The same standard applies to testimonials. Ask the network whether its advertisers can provide substantiation data for the results depicted in promotional materials.
The FTC will scrutinize your weight loss claims more aggressively than claims in virtually any other consumer category. The agency has decades of enforcement history in weight loss and treats it as a priority. Your advertising claims must be truthful, substantiated by competent and reliable scientific evidence, and representative of typical results. If your product or program produces an average weight loss of 8 pounds over 12 weeks, your affiliate materials should reflect that reality, not the outlier who lost 40 pounds. Affiliates will amplify whatever claims you permit. Tight claim guidelines, mandatory creative pre-approval, and active compliance monitoring are the minimum.
Fake reviews and testimonials are now explicitly on the FTC’s enforcement radar. The FTC’s Consumer Review Rule (effective October 2024) gives the agency civil penalty authority over fake reviews, undisclosed insider testimonials, and review suppression. The NextMed case targeted fake reviews and fabricated testimonials as part of the weight loss advertising enforcement. Your affiliate program should prohibit fake reviews and testimonials explicitly, and your network should monitor for affiliates fabricating social proof.
GLP-1 program compliance requires particular attention. If your weight loss program involves prescription medications, the advertising claims are subject to both FTC advertising standards and FDA pharmaceutical advertising regulations. Telehealth programs that market GLP-1 access must clearly disclose pricing, membership terms, and the distinction between marketing claims and actual medical eligibility requirements. The rapid growth of this category has attracted operators prioritizing customer acquisition over compliance. Differentiate your program through transparent marketing practices.
Subscription billing on weight loss programs is subject to the same ROSCA requirements as nutra. Clear disclosure of subscription terms before the consumer is charged, easy cancellation processes, and honest product representations are legal requirements, not optional best practices. Chargebacks on weight loss subscriptions follow the same patterns as nutra. Control affiliate promotional claims to manage chargeback rates.
Treat the category as closed. The FDA resolved the semaglutide shortage in February 2025, which removed the basis for shortage-driven compounding, and enforcement discretion for outsourcing facilities ended that May. In March 2026 the agency issued more than fifty warning letters to telehealth firms and compounders, and in April 2026 proposed removing semaglutide from the 503B bulks list. Hims, Ro and the other large platforms have exited. Patient-specific compounding continues in narrow circumstances; broad promotion does not.
Specific pounds-lost figures, results without diet or exercise, before-and-after imagery that is not typical, and clinically-proven language without adequate evidence. Weight loss has been an explicit FTC enforcement priority for decades. The December 2025 order against telehealth provider NextMed added deceptive GLP-1 pricing, unsubstantiated claims and fake reviews to that record.
Yes. The FTC Consumer Review Rule, effective October 2024, gives the agency civil penalty authority over fake reviews, undisclosed insider testimonials and review suppression. That reaches whoever published them. A testimonial supplied by a network is still your publication once it is on your page, so ask what substantiation sits behind it.
More than the category name suggests. Supplements run on trial-to-subscription rebill with the chargeback profile that implies. Meal delivery and programmes run on subscription economics with better retention. Fitness apps pay on trial or activation. Telehealth pays on lead or consultation. They share an audience and almost nothing else, so evaluate each on its own billing model rather than as weight loss.
Clear disclosure of the subscription terms before the consumer is charged, informed consent to the recurring charge, and a simple cancellation route. It survived the separate FTC negative-option rule being struck down in 2025. Because the deceptive impression is usually formed on the affiliate page, put the price, the billing date and the cancellation route beside the call to action rather than in a footer.
Disclaimer: The information provided in this guide is intended solely as an educational starting point for further independent research and does not constitute legal, regulatory, or financial advice. Advertising rules, statutory requirements, and regulatory enforcement priorities change frequently. Readers should not rely on this content as a substitute for professional legal counsel or formal compliance audits. Publishers and advertisers are responsible for independently verifying all compliance requirements applicable to their specific offers, geographies, and promotional methods.
Last reviewed September 2026.
Independent performance-marketing intelligence, straight to your inbox.